The Financial Industry Regulatory Authority Inc. has barred former Goldman Sachs research analyst Brian Maguire for twice purchasing securities after he learned a fellow analyst was upgrading his recommendation in impending research reports and for lying to Finra staff about his trading.
Finra found that in April 2020 and June 2020, Maguire purchased shares of two companies in undisclosed accounts after receiving material nonpublic information. This information consisted of internal emails disclosing that the research analyst covering those companies was upgrading his recommendation from “Neutral” to “Buy” in impending research reports. Maguire purchased the shares after the upgrades were approved internally but before the research reports announcing those upgrades were published.
In settling this matter, Maguire neither admitted nor denied the charges, but consented to the entry of Finra’s findings.
$1.7M invested from an inheritance. Then the phone went dead.
The pre-IPO platform sold $430M in units while allegedly rigging prices behind the scenes.
A Nationwide survey finds 47% of GLP-1 users have never discussed the drugs’ financial impact with an advisor, even as many dip into savings.
The hundreds of millions of dollars from a sale of Inspired Healthcare properties does not mean an immediate windfall for investors.
Its SEC filings said one thing - a congressional probe said another.
Knighthead Life entered the market with a competitive MYGA. A strong launch earned advisor confidence and paved the way for FIAs.
As AI makes financial information more accessible than ever, Lana Hock explains why human judgment, trust, and empathy remain the qualities clients value most in a financial advisor
